Drug Approval | January 08, 2026
GSK’s Exdensur wins Japanese nod for severe asthma
The approval follows robust data from the SWIFT and ANCHOR Phase III trials
The approval follows robust data from the SWIFT and ANCHOR Phase III trials
The trial aims to measure AF burden—the percentage of time patients spend in arrhythmia—as its primary efficacy endpoint
It is currently the only vaccine authorized by the Drug Controller General of India (DCGI) for active immunization against HEV in adults aged 18 to 65
The SNS records neural activity from 60 channels across four brain regions—far exceeding current commercial devices
The filing clears the regulatory path for potential first-in-human trials and marks a key advance in the company’s chronic inflammatory disease pipeline
The Phase II study will assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of 9MW3811 in patients with pathological scarring
The resubmission of BLA for MOLBREEVI names Fujifilm as the drug substance manufacturer
Theracor is derived from human umbilical cord extracellular matrix (ECM) and is designed to cover, protect, and maintain a moist wound environment
Under his leadership, Chidamide became China’s first original small-molecule anti-tumor innovative drug and the country’s first pharmaceutical product globally licensed out
TMS offers new hope to patients suffering from stroke, migraine, neuropathic pain, depression, and other disorders
Subscribe To Our Newsletter & Stay Updated
